WallStSmart

Emerson Electric Company (EMR)vsGlaxoSmithKline PLC ADR (GSK)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GlaxoSmithKline PLC ADR generates 79% more annual revenue ($32.78B vs $18.32B). GSK leads profitability with a 17.8% profit margin vs 13.4%. GSK appears more attractively valued with a PEG of 0.50. GSK earns a higher WallStSmart Score of 66/100 (B-).

EMR

Buy

59

out of 100

Grade: C

Growth: 6.0Profit: 6.5Value: 4.3Quality: 5.3
Piotroski: 5/9Altman Z: 2.57

GSK

Strong Buy

66

out of 100

Grade: B-

Growth: 4.7Profit: 9.0Value: 7.3Quality: 4.0
Piotroski: 5/9Altman Z: 1.26
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for EMR.

GSKFair Value (-3.1%)

Margin of Safety

-3.1%

Fair Value

$56.71

Current Price

$50.41

$6.30 premium

UndervaluedFair: $56.71Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EMR3 strengths · Avg: 8.3/10
Market CapQuality
$79.02B9/10

Large-cap with strong market position

Operating MarginProfitability
24.2%8/10

Strong operational efficiency at 24.2%

EPS GrowthGrowth
27.9%8/10

Earnings expanding 27.9% YoY

GSK5 strengths · Avg: 9.4/10
PEG RatioValuation
0.5010/10

Growing faster than its price suggests

Return on EquityProfitability
40.9%10/10

Every $100 of equity generates 41 in profit

Operating MarginProfitability
36.3%10/10

Strong operational efficiency at 36.3%

Market CapQuality
$101.38B9/10

Large-cap with strong market position

P/E RatioValuation
13.1x8/10

Attractively priced relative to earnings

Areas to Watch

EMR3 concerns · Avg: 4.0/10
PEG RatioValuation
1.774/10

Expensive relative to growth rate

P/E RatioValuation
32.7x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
2.9%4/10

2.9% revenue growth

GSK3 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

Debt/EquityHealth
1.103/10

Elevated debt levels

Altman Z-ScoreHealth
1.262/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : EMR

The strongest argument for EMR centers on Market Cap, Operating Margin, EPS Growth.

Bull Case : GSK

The strongest argument for GSK centers on PEG Ratio, Return on Equity, Operating Margin. Profitability is solid with margins at 17.8% and operating margin at 36.3%. PEG of 0.50 suggests the stock is reasonably priced for its growth.

Bear Case : EMR

The primary concerns for EMR are PEG Ratio, P/E Ratio, Revenue Growth.

Bear Case : GSK

The primary concerns for GSK are Revenue Growth, Debt/Equity, Altman Z-Score.

Key Dynamics to Monitor

EMR carries more volatility with a beta of 1.25 — expect wider price swings.

EMR is growing revenue faster at 2.9% — sustainability is the question.

GSK generates stronger free cash flow (698M), providing more financial flexibility.

Monitor SPECIALTY INDUSTRIAL MACHINERY industry trends, competitive dynamics, and regulatory changes.

Bottom Line

GSK scores higher overall (66/100 vs 59/100), backed by strong 17.8% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Emerson Electric Company

INDUSTRIALS · SPECIALTY INDUSTRIAL MACHINERY · USA

Emerson Electric Co. is an American multinational corporation headquartered in Ferguson, Missouri. The Fortune 500 company manufactures products and provides engineering services for a wide range of industrial, commercial, and consumer markets.

GlaxoSmithKline PLC ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

GlaxoSmithKline plc is dedicated to the creation, discovery, development, manufacture and marketing of pharmaceuticals, vaccines, over-the-counter drugs and health-related consumer products in the UK, US and internationally. The company is headquartered in Brentford, the United Kingdom.

Want to dig deeper into these stocks?